Your browser doesn't support javascript.
Establishing the prevalence of common tissue-specific autoantibodies following severe acute respiratory syndrome coronavirus 2 infection.
Richter, Alex G; Shields, Adrian M; Karim, Abid; Birch, David; Faustini, Sian E; Steadman, Lora; Ward, Kerensa; Plant, Timothy; Reynolds, Gary; Veenith, Tonny; Cunningham, Adam F; Drayson, Mark T; Wraith, David C.
  • Richter AG; Clinical Immunology Service, Institute for Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Shields AM; Clinical Immunology Service, Institute for Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Karim A; Clinical Immunology Service, Institute for Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Birch D; Clinical Immunology Service, Institute for Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Faustini SE; Clinical Immunology Service, Institute for Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Steadman L; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Ward K; Clinical Immunology Service, Institute for Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Plant T; Clinical Immunology Service, Institute for Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Reynolds G; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Veenith T; Department of Critical Care Medicine, University Hospitals Birmingham NHS Trust, Birmingham, UK.
  • Cunningham AF; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Drayson MT; Clinical Immunology Service, Institute for Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
  • Wraith DC; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Clin Exp Immunol ; 205(2): 99-105, 2021 08.
Article in English | MEDLINE | ID: covidwho-1273082
Semantic information from SemMedBD (by NLM)
1. Autoantibodies PART_OF Tissue specific
Subject
Autoantibodies
Predicate
PART_OF
Object
Tissue specific
2. Virus Diseases NEG_CAUSES Symptoms
Subject
Virus Diseases
Predicate
NEG_CAUSES
Object
Symptoms
3. Autoantibodies ASSOCIATED_WITH COVID-19
Subject
Autoantibodies
Predicate
ASSOCIATED_WITH
Object
COVID-19
4. COVID-19 AFFECTS 2019 novel coronavirus
Subject
COVID-19
Predicate
AFFECTS
Object
2019 novel coronavirus
5. Persons LOCATION_OF Autoantibodies
Subject
Persons
Predicate
LOCATION_OF
Object
Autoantibodies
6. Autoantibodies compared_with Autoantibodies
Subject
Autoantibodies
Predicate
compared_with
Object
Autoantibodies
7. Detection AFFECTS Viral respiratory infection
Subject
Detection
Predicate
AFFECTS
Object
Viral respiratory infection
8. Autoantibodies PART_OF Tissue specific
Subject
Autoantibodies
Predicate
PART_OF
Object
Tissue specific
9. Virus Diseases NEG_CAUSES Symptoms
Subject
Virus Diseases
Predicate
NEG_CAUSES
Object
Symptoms
10. Autoantibodies ASSOCIATED_WITH COVID-19
Subject
Autoantibodies
Predicate
ASSOCIATED_WITH
Object
COVID-19
11. COVID-19 AFFECTS 2019 novel coronavirus
Subject
COVID-19
Predicate
AFFECTS
Object
2019 novel coronavirus
12. Persons LOCATION_OF Autoantibodies
Subject
Persons
Predicate
LOCATION_OF
Object
Autoantibodies
13. Autoantibodies compared_with Autoantibodies
Subject
Autoantibodies
Predicate
compared_with
Object
Autoantibodies
14. Detection AFFECTS Viral respiratory infection
Subject
Detection
Predicate
AFFECTS
Object
Viral respiratory infection
ABSTRACT
Coronavirus 19 (COVID-19) has been associated with both transient and persistent systemic symptoms that do not appear to be a direct consequence of viral infection. The generation of autoantibodies has been proposed as a mechanism to explain these symptoms. To understand the prevalence of autoantibodies associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, we investigated the frequency and specificity of clinically relevant autoantibodies in 84 individuals previously infected with SARS-CoV-2, suffering from COVID-19 of varying severity in both the acute and convalescent setting. These were compared with results from 32 individuals who were on the intensive therapy unit (ITU) for non-COVID reasons. We demonstrate a higher frequency of autoantibodies in the COVID-19 ITU group compared with non-COVID-19 ITU disease control patients and that autoantibodies were also found in the serum 3-5 months post-COVID-19 infection. Non-COVID patients displayed a diverse pattern of autoantibodies; in contrast, the COVID-19 groups had a more restricted panel of autoantibodies including skin, skeletal muscle and cardiac antibodies. Our results demonstrate that respiratory viral infection with SARS-CoV-2 is associated with the detection of a limited profile of tissue-specific autoantibodies, detectable using routine clinical immunology assays. Further studies are required to determine whether these autoantibodies are specific to SARS-CoV-2 or a phenomenon arising from severe viral infections and to determine the clinical significance of these autoantibodies.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Autoantibodies / SARS-CoV-2 / COVID-19 / Antibody Specificity Type of study: Prevalence study / Randomized controlled trials / Risk factors Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Clin Exp Immunol Year: 2021 Document Type: Article Affiliation country: Cei.13623

Full text: Available Collection: International databases Database: MEDLINE Main subject: Autoantibodies / SARS-CoV-2 / COVID-19 / Antibody Specificity Type of study: Prevalence study / Randomized controlled trials / Risk factors Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Clin Exp Immunol Year: 2021 Document Type: Article Affiliation country: Cei.13623